EA020412B1 - Иммунологический мониторинг на основе ip-10 - Google Patents
Иммунологический мониторинг на основе ip-10 Download PDFInfo
- Publication number
- EA020412B1 EA020412B1 EA200970246A EA200970246A EA020412B1 EA 020412 B1 EA020412 B1 EA 020412B1 EA 200970246 A EA200970246 A EA 200970246A EA 200970246 A EA200970246 A EA 200970246A EA 020412 B1 EA020412 B1 EA 020412B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- level
- antigen
- sample
- test
- infection
- Prior art date
Links
- 230000001900 immune effect Effects 0.000 title claims abstract description 43
- 238000012544 monitoring process Methods 0.000 title description 11
- 239000000427 antigen Substances 0.000 claims abstract description 326
- 108091007433 antigens Proteins 0.000 claims abstract description 325
- 102000036639 antigens Human genes 0.000 claims abstract description 325
- 208000015181 infectious disease Diseases 0.000 claims abstract description 136
- 238000000034 method Methods 0.000 claims abstract description 111
- 244000005700 microbiome Species 0.000 claims abstract description 45
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 230000001404 mediated effect Effects 0.000 claims abstract description 21
- 230000028993 immune response Effects 0.000 claims abstract description 17
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- 241000222722 Leishmania <genus> Species 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims abstract description 8
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 7
- 241000711573 Coronaviridae Species 0.000 claims abstract description 6
- 241000701022 Cytomegalovirus Species 0.000 claims abstract description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 6
- 241000709661 Enterovirus Species 0.000 claims abstract description 5
- 241000192125 Firmicutes Species 0.000 claims abstract description 5
- 241000710831 Flavivirus Species 0.000 claims abstract description 5
- 208000005176 Hepatitis C Diseases 0.000 claims abstract description 5
- 241000589902 Leptospira Species 0.000 claims abstract description 5
- 241000712045 Morbillivirus Species 0.000 claims abstract description 5
- 241000244206 Nematoda Species 0.000 claims abstract description 5
- 241000224016 Plasmodium Species 0.000 claims abstract description 5
- 241000710801 Rubivirus Species 0.000 claims abstract description 5
- 241000589886 Treponema Species 0.000 claims abstract description 5
- 241000607598 Vibrio Species 0.000 claims abstract description 5
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims abstract description 5
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 5
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims abstract description 4
- 241000869417 Trematodes Species 0.000 claims abstract description 4
- 238000012360 testing method Methods 0.000 claims description 204
- 230000004044 response Effects 0.000 claims description 116
- 210000004027 cell Anatomy 0.000 claims description 46
- 238000005259 measurement Methods 0.000 claims description 27
- 230000001419 dependent effect Effects 0.000 claims description 16
- 208000032420 Latent Infection Diseases 0.000 claims description 15
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 claims description 15
- 238000003556 assay Methods 0.000 claims description 11
- 238000003752 polymerase chain reaction Methods 0.000 claims description 7
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 5
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 230000002035 prolonged effect Effects 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 239000013641 positive control Substances 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 2
- 229940126530 T cell activator Drugs 0.000 claims description 2
- 238000003119 immunoblot Methods 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 238000010324 immunological assay Methods 0.000 claims 1
- 239000002594 sorbent Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract description 36
- 241000282414 Homo sapiens Species 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 241001115402 Ebolavirus Species 0.000 abstract description 4
- 241001115401 Marburgvirus Species 0.000 abstract description 4
- 244000144972 livestock Species 0.000 abstract description 4
- 241000194033 Enterococcus Species 0.000 abstract description 3
- 241000589968 Borrelia Species 0.000 abstract 1
- 208000007514 Herpes zoster Diseases 0.000 abstract 1
- 241000186781 Listeria Species 0.000 abstract 1
- 208000016604 Lyme disease Diseases 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 241000233870 Pneumocystis Species 0.000 abstract 1
- 241000223997 Toxoplasma gondii Species 0.000 abstract 1
- 241000223104 Trypanosoma Species 0.000 abstract 1
- 201000000317 pneumocystosis Diseases 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 137
- 210000004369 blood Anatomy 0.000 description 80
- 239000008280 blood Substances 0.000 description 80
- 201000008827 tuberculosis Diseases 0.000 description 78
- 230000035945 sensitivity Effects 0.000 description 53
- 230000000638 stimulation Effects 0.000 description 47
- 238000004458 analytical method Methods 0.000 description 46
- 239000000090 biomarker Substances 0.000 description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 239000003226 mitogen Substances 0.000 description 40
- 230000009257 reactivity Effects 0.000 description 39
- 201000010099 disease Diseases 0.000 description 37
- 238000011534 incubation Methods 0.000 description 34
- 210000002381 plasma Anatomy 0.000 description 34
- 239000003550 marker Substances 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 31
- 238000004519 manufacturing process Methods 0.000 description 28
- 238000003745 diagnosis Methods 0.000 description 25
- 239000012642 immune effector Substances 0.000 description 23
- 229940121354 immunomodulator Drugs 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 238000010790 dilution Methods 0.000 description 18
- 239000012895 dilution Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 208000035473 Communicable disease Diseases 0.000 description 17
- 230000007503 antigenic stimulation Effects 0.000 description 17
- 238000001514 detection method Methods 0.000 description 17
- 241000606161 Chlamydia Species 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 208000036981 active tuberculosis Diseases 0.000 description 15
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
- 230000000890 antigenic effect Effects 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000003018 immunoassay Methods 0.000 description 11
- 230000002269 spontaneous effect Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 108010047620 Phytohemagglutinins Proteins 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 230000001885 phytohemagglutinin Effects 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 102000019034 Chemokines Human genes 0.000 description 8
- 108010012236 Chemokines Proteins 0.000 description 8
- 230000016396 cytokine production Effects 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 239000012678 infectious agent Substances 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241000193830 Bacillus <bacterium> Species 0.000 description 7
- 206010061041 Chlamydial infection Diseases 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000009260 cross reactivity Effects 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 102000008070 Interferon-gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 206010065048 Latent tuberculosis Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 201000000902 chlamydia Diseases 0.000 description 6
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 229960003130 interferon gamma Drugs 0.000 description 6
- 201000004792 malaria Diseases 0.000 description 6
- 238000000386 microscopy Methods 0.000 description 6
- 210000004910 pleural fluid Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 5
- 238000009640 blood culture Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003399 chemotactic effect Effects 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 229960001005 tuberculin Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- -1 without limitation Substances 0.000 description 4
- 208000001490 Dengue Diseases 0.000 description 3
- 206010012310 Dengue fever Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 101710116435 Outer membrane protein Proteins 0.000 description 3
- 241000702670 Rotavirus Species 0.000 description 3
- 239000002160 alpha blocker Substances 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 208000025729 dengue disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 210000001733 follicular fluid Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 208000033353 latent tuberculosis infection Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000002297 mitogenic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 2
- 208000031504 Asymptomatic Infections Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 102100021794 Microtubule-associated protein 4 Human genes 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101100131116 Oryza sativa subsp. japonica MPK3 gene Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 241000242678 Schistosoma Species 0.000 description 2
- 101100456045 Schizosaccharomyces pombe (strain 972 / ATCC 24843) map3 gene Proteins 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000000104 diagnostic biomarker Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000006674 extrapulmonary tuberculosis Diseases 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108060003552 hemocyanin Proteins 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000012502 risk assessment Methods 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 201000004409 schistosomiasis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 108010004486 trans-sialidase Proteins 0.000 description 2
- 201000002311 trypanosomiasis Diseases 0.000 description 2
- 239000013026 undiluted sample Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 206010051226 Campylobacter infection Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 241000498849 Chlamydiales Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241001342895 Chorus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 206010013453 Disseminated tuberculosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010015932 Eye infection chlamydial Diseases 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001290006 Fissurella Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 description 1
- 101001100332 Homo sapiens Probable RNA-binding protein 46 Proteins 0.000 description 1
- 101000697347 Homo sapiens Translocon-associated protein subunit gamma Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 101710149059 Large cysteine-rich periplasmic protein OmcB Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- 201000006836 Miliary Tuberculosis Diseases 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010058674 Pelvic Infection Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 description 1
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 1
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 102100038818 Probable RNA-binding protein 46 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 102220469221 S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B_E18A_mutation Human genes 0.000 description 1
- 101100428373 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) POR1 gene Proteins 0.000 description 1
- 241000369757 Sapovirus Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 101100018382 Shigella flexneri icsP gene Proteins 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100028160 Translocon-associated protein subunit gamma Human genes 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 208000005469 Vivax Malaria Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000007234 antiinflammatory process Effects 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- HAORKNGNJCEJBX-UHFFFAOYSA-N cyprodinil Chemical compound N=1C(C)=CC(C2CC2)=NC=1NC1=CC=CC=C1 HAORKNGNJCEJBX-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 101150014428 mpt64 gene Proteins 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 101150016099 omcA gene Proteins 0.000 description 1
- 101150087557 omcB gene Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- IXJYMUFPNFFKIB-FMONCPFKSA-N pomp protocol Chemical compound S=C1N=CNC2=C1NC=N2.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IXJYMUFPNFFKIB-FMONCPFKSA-N 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 101150022349 sopA gene Proteins 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/32—Mycobacterium
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Jellies, Jams, And Syrups (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200601145 | 2006-09-05 | ||
| DKPA200700262 | 2007-02-20 | ||
| PCT/DK2007/000399 WO2008028489A2 (en) | 2006-09-05 | 2007-09-05 | Ip-i0 based immunological monitoring |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200970246A1 EA200970246A1 (ru) | 2009-10-30 |
| EA020412B1 true EA020412B1 (ru) | 2014-11-28 |
Family
ID=38716188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200970246A EA020412B1 (ru) | 2006-09-05 | 2007-09-05 | Иммунологический мониторинг на основе ip-10 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8026076B2 (enExample) |
| EP (4) | EP2128612B1 (enExample) |
| JP (1) | JP5805368B2 (enExample) |
| KR (1) | KR101248491B1 (enExample) |
| CN (1) | CN101523217B (enExample) |
| AT (1) | ATE504000T1 (enExample) |
| AU (1) | AU2007294293B2 (enExample) |
| BR (1) | BRPI0714744B8 (enExample) |
| CA (1) | CA2662429C (enExample) |
| DE (1) | DE602007013620D1 (enExample) |
| DK (2) | DK2128612T3 (enExample) |
| EA (1) | EA020412B1 (enExample) |
| IN (1) | IN2015DN03125A (enExample) |
| PL (1) | PL2128612T3 (enExample) |
| PT (1) | PT2128612E (enExample) |
| WO (1) | WO2008028489A2 (enExample) |
| ZA (1) | ZA200902297B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0722105D0 (en) | 2007-11-10 | 2007-12-19 | Sec Dep For Environment Food A | Antigens |
| MX2010014556A (es) * | 2008-06-25 | 2011-07-28 | Baylor Res Inst | Firma transcripcional de sangre por infeccion de mycobacterium tuberculosis. |
| CN102105786B (zh) * | 2008-07-25 | 2014-10-29 | 赛乐思迪斯有限公司 | 诊断方法 |
| CN102246040B (zh) * | 2008-12-15 | 2014-11-05 | 安特鲁姆生物技术（私人）有限公司 | 用于诊断结核病的方法和装置 |
| GB0906215D0 (en) | 2009-04-09 | 2009-05-20 | Lalvani Ajit | Diagnostic test |
| DK2365332T3 (da) * | 2010-03-10 | 2013-08-26 | Pasteur Institut | HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser |
| US20130078657A1 (en) * | 2010-05-04 | 2013-03-28 | Hvidovre Hospital | Hyperthermia augmented in-vitro immune recognition |
| WO2012076020A1 (en) * | 2010-12-09 | 2012-06-14 | Hvidovre Hospital | A method for generating, storing, transporting, eluting and detecting clinical relevant information in plasma using filter paper |
| WO2012139591A1 (en) | 2011-04-13 | 2012-10-18 | Hvidovre Hospital | Monitoring liver fibrosis in a hepatitis c infected patient |
| EP2702076A1 (en) * | 2011-04-29 | 2014-03-05 | Bristol-Myers Squibb Company | Ip-10 antibody dosage escalation regimens |
| CN103122033B (zh) * | 2011-11-21 | 2015-08-19 | 厦门大学 | 一种嵌合重组抗原及其用途 |
| WO2013087917A1 (en) * | 2011-12-15 | 2013-06-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for diagnosing latent tuberculosis infection |
| ES2886979T3 (es) | 2012-02-09 | 2021-12-21 | Memed Diagnostics Ltd | Distintivos y determinantes para diagnosticar infecciones y métodos para usarlos |
| WO2013168876A1 (ko) | 2012-05-11 | 2013-11-14 | 가톨릭대학교 산학협력단 | 이식 후 면역 상태를 모니터링 하는 키트 및 이를 이용한 면역 상태의 모니터링 방법 |
| JP6102438B2 (ja) | 2012-05-30 | 2017-03-29 | 三菱化学株式会社 | 軸受部材、端部部材、感光体ドラムユニット、プロセスカートリッジ、及び軸受部材の製造方法 |
| JP6020237B2 (ja) | 2013-02-15 | 2016-11-02 | 三菱化学株式会社 | 軸受部材、端部部材、感光体ドラムユニット、及び軸受部材の製造方法 |
| WO2015038624A1 (en) | 2013-09-10 | 2015-03-19 | Immusant, Inc. | Dosage of a gluten peptide composition |
| KR101542510B1 (ko) | 2014-01-15 | 2015-08-18 | 대한민국 | 초기 hiv-1 감염자에서 급속한 aids 질환 진행을 예측하기 위한 ip-10의 용도 |
| RU2016137685A (ru) * | 2014-02-26 | 2018-03-29 | Стелленбос Юниверсити | Способ диагностики туберкулеза |
| KR101590324B1 (ko) * | 2014-04-24 | 2016-02-01 | 연세대학교 산학협력단 | 향상된 결핵 진단 방법 |
| WO2015164747A1 (en) * | 2014-04-24 | 2015-10-29 | Immusant, Inc. | Methods for diagnosing celiac disease using circulating cytokines/chemokines |
| EP3180621B1 (en) | 2014-08-14 | 2020-04-01 | Memed Diagnostics Ltd. | Computational analysis of biological data using manifold and a hyperplane |
| KR101748296B1 (ko) | 2014-09-04 | 2017-06-19 | 연세대학교 산학협력단 | 마이코박테리움 압세수스 복합체 감염 폐질환 진단용 바이오마커 조성물 |
| US10370718B2 (en) | 2014-09-29 | 2019-08-06 | Immusant, Inc. | Use of HLA genetic status to assess or select treatment of celiac disease |
| EP3221344A2 (en) | 2014-11-21 | 2017-09-27 | Immusant Inc. | Peptides for use in treatment and diagnosis of type 1 diabetes |
| CN111624345A (zh) | 2014-12-11 | 2020-09-04 | 米密德诊断学有限公司 | 用于诊断多种感染的标记组合及其使用方法 |
| CN104897893A (zh) * | 2015-06-10 | 2015-09-09 | 复旦大学附属华山医院 | 一种基于结核特异性il-31检测的诊断结核分枝杆菌感染的试剂盒 |
| IL287757B (en) | 2016-03-03 | 2022-07-01 | Memed Diagnostics Ltd | Analyzing rna for diagnosing infection type |
| CA3015046A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Rna determinants for distinguishing between bacterial and viral infections |
| CN109804245B (zh) * | 2016-07-10 | 2022-10-25 | 米密德诊断学有限公司 | 感染的早期诊断 |
| EP4141448A1 (en) | 2016-07-10 | 2023-03-01 | MeMed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| WO2018060999A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification |
| WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| CN108548917B (zh) * | 2018-03-01 | 2021-07-06 | 广州市雷德生物科技有限公司 | 一种记忆性免疫细胞的检测体系及其应用 |
| WO2020127908A2 (en) | 2018-12-20 | 2020-06-25 | Lophius Biosciences Gmbh | Method of detecting infection with pathogens causing tuberculosis |
| WO2021255237A1 (en) | 2020-06-19 | 2021-12-23 | Mikrogen Gmbh | Method of detecting infection with pathogens causing tuberculosis |
| WO2022169842A1 (en) * | 2021-02-02 | 2022-08-11 | Revelation Biosciences, Inc. | Rapid detection kits and methods for diagnosing infections of the respiratory tract |
| WO2022240887A1 (en) * | 2021-05-10 | 2022-11-17 | Icahn School Of Medicine At Mount Sinai | Methods for detecting and staging cellular viral immune responses |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965192A (en) * | 1984-12-05 | 1990-10-23 | Anda Biologicals | A60-antigen from Mycobacteria and use thereof as tuberculin and as vaccine |
| US20030143641A1 (en) * | 2000-10-18 | 2003-07-31 | Brice Gary Todd | Novel assay for detecting immune responses involving antigen specific cytokine and/or antigen specific cytokine secreting T-cells |
| WO2003063759A2 (en) * | 2002-01-31 | 2003-08-07 | Peptor Ltd. | Hsp peptides and analogs for modulation of immune responses via antigen presenting cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1200466A2 (en) * | 1999-07-13 | 2002-05-02 | Statens Serum Institut | Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosisesat-6 gene family |
| US20040038201A1 (en) | 2002-01-22 | 2004-02-26 | Whitehead Institute For Biomedical Research | Diagnostic and therapeutic applications for biomarkers of infection |
| AU2002952548A0 (en) | 2002-11-08 | 2002-11-21 | Cellestis Limited | Diagnostic assay |
| WO2005012907A1 (en) * | 2003-08-01 | 2005-02-10 | Renovar, Inc. | Systems and methods for characterizing kidney diseases |
| US7575862B2 (en) * | 2003-12-09 | 2009-08-18 | Asiagen Corporation | Assay systems, kits and methods for detecting microorganisms |
| GB2427471B (en) | 2004-03-04 | 2009-07-22 | Laura Manuelidis | Pre-symptomatic markers for diseases associated with transmissable spongiform encephalopaties |
| US20060051358A1 (en) * | 2004-05-24 | 2006-03-09 | Baylor Research Institute | Immune response assessment method |
| US7332294B2 (en) * | 2004-08-17 | 2008-02-19 | University Health Network | CXCL10-based diagnosis and treatment of respiratory illnesses |
| CA2478138A1 (en) | 2004-08-17 | 2006-02-17 | University Health Network | Cxcl10-based diagnosis and treatment of respiratory illnesses |
| EP1885852B1 (en) * | 2005-05-05 | 2010-08-25 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Methods and compositions for detecting immune responses |
| EP1767937A1 (en) * | 2005-09-27 | 2007-03-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of diagnosis of tuberculosis related immune restoration syndrome (IRS) |
| EP1994409A2 (en) * | 2006-03-14 | 2008-11-26 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
| CN1866023B (zh) * | 2006-05-25 | 2010-11-03 | 上海市肺科医院 | 一种同步检测多种结核杆菌特异性分泌抗原的方法 |
-
2007
- 2007-09-05 IN IN3125DEN2015 patent/IN2015DN03125A/en unknown
- 2007-09-05 DE DE602007013620T patent/DE602007013620D1/de active Active
- 2007-09-05 CN CN200780032976.5A patent/CN101523217B/zh active Active
- 2007-09-05 AU AU2007294293A patent/AU2007294293B2/en active Active
- 2007-09-05 DK DK09170735.6T patent/DK2128612T3/da active
- 2007-09-05 AT AT09170735T patent/ATE504000T1/de active
- 2007-09-05 PT PT09170735T patent/PT2128612E/pt unknown
- 2007-09-05 EP EP09170735A patent/EP2128612B1/en active Active
- 2007-09-05 EP EP07801367A patent/EP2059816A2/en active Pending
- 2007-09-05 PL PL09170735T patent/PL2128612T3/pl unknown
- 2007-09-05 EP EP10168333A patent/EP2228651A1/en not_active Withdrawn
- 2007-09-05 EP EP10180905.1A patent/EP2261658B1/en active Active
- 2007-09-05 US US12/438,515 patent/US8026076B2/en active Active
- 2007-09-05 JP JP2009527015A patent/JP5805368B2/ja active Active
- 2007-09-05 WO PCT/DK2007/000399 patent/WO2008028489A2/en not_active Ceased
- 2007-09-05 EA EA200970246A patent/EA020412B1/ru unknown
- 2007-09-05 DK DK10180905T patent/DK2261658T3/en active
- 2007-09-05 CA CA2662429A patent/CA2662429C/en active Active
- 2007-09-05 BR BRPI0714744A patent/BRPI0714744B8/pt active IP Right Grant
- 2007-09-05 KR KR1020097006853A patent/KR101248491B1/ko active Active
-
2009
- 2009-04-02 ZA ZA2009/02297A patent/ZA200902297B/en unknown
-
2011
- 2011-09-26 US US13/245,521 patent/US20120015386A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965192A (en) * | 1984-12-05 | 1990-10-23 | Anda Biologicals | A60-antigen from Mycobacteria and use thereof as tuberculin and as vaccine |
| US20030143641A1 (en) * | 2000-10-18 | 2003-07-31 | Brice Gary Todd | Novel assay for detecting immune responses involving antigen specific cytokine and/or antigen specific cytokine secreting T-cells |
| WO2003063759A2 (en) * | 2002-01-31 | 2003-08-07 | Peptor Ltd. | Hsp peptides and analogs for modulation of immune responses via antigen presenting cells |
Non-Patent Citations (11)
| Title |
|---|
| ANANABA G.A. ET AL.: "Chemokine and chemokine receptor regulation of Th1 response against Chlamydia". ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 101, 2001, page 347, XP008080144 & 101ST GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY; ORLANDO, FL, USA; MAY 20-24, 2001, ISSN: 1060-2011, abstract * |
| AZZURRI A. ET AL.: "IFN-gama-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection". MICROBES AND INFECTION, ELSEVIER, PARIS, FR, vol. 7, no. 1, January 2005 (2005-01), pages 1-8, XP004742531, ISSN: 1286-4579, the whole document in particular: abstract page 5, left-hand column, last paragraph - right-hand column, last paragraph * |
| BELAY TESFAYE ET AL.: "Chemokine and chemokine receptor dynamics during genital chlamydial infection". INFECTION AND IMMUNITY, vol. 70, no. 2, February 2002 (2002-02), pages 844-850, XP002437891, ISSN: 0019-9567, the whole document in particular: abstract figure 2 page 845, left-hand column, last paragraph - right-hand column, line 18 * |
| BOURGARIT ANNE ET AL.: "Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients". AIDS, LONDON, GB, vol. 20, no. 2, January 2006 (2006-01), pages F1-F7, XP002418216, ISSN: 0269-9370, the whole document in particular: abstract page F2-F3: Methods, page F3, right-hand column, paragraph 2-3, figure 1 * |
| FERRERO ELISABETTA ET AL.: "Macrophages exposed to Mycobacterium tuberculosis release chemokines able to recruit selected leucocyte subpopulations: Focus on gammadelta cells". IMMUNOLOGY, vol. 108, no. 3, March 2003 (2003-03), pages 365-374, XP002472604, ISSN: 0019-2805, the whole document in particular: abstract page 367, left-hand column, line 12-37, table 1, page 368, right-hand column, line 1-17 * |
| KREMLEV SERGEY G. ET AL.: "Differential expression of chemokines and chemokine receptors during microglial activation and inhibition". JOURNAL OF NEUROIMMUNOLOGY, vol. 149, no. 1-2, April 2004 (2004-04), pages 1-9, XP002472607, ISSN: 0165-5728, the whole document in particular: abstract figure 1 * |
| LINDHOLM C. ET AL.: "Induction of chemokine and cytokine responses by Helicobacter pylori in human stomach explants". SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 36, no. 10, October 2001 (2001-10), pages 1022-1029, XP008086376, ISSN: 0036-5521, the whole document abstract * |
| MOLESWORTH-KENYON S.J. ET AL.: "ABUNDANT EXPRESSION OF IP-10 AND MIG IN THE HSV-1 INFECTED CORNEA". INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 45, no. 1, April 2004 (2004-04), page U127, XP008080137, ISSN: 0146-0404, the whole document * |
| NAGARAJAN UMA M. ET AL.: "Chlamydia trachomatis induces expression of IFN-gamma-inducible protein 10 and IFN-beta independent of TLR2 and TLR4, but largely dependent on MyD88". JOURNAL OF IMMUNOLOGY, vol. 175, no. 1, July 2005 (2005-07), pages 450-460, XP008086385, ISSN: 0022-1767, the whole document in particular: abstract page 451, right-hand column, line 44-68, page 453, right-hand column, line 7 - page 454, left-hand column, line 26 * |
| RUHWALD MORTEN ET AL.: "CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7.". MICROBES AND INFECTION/INSTITUT PASTEUR, JUN 2007, vol. 9, no. 7, June 2007 (2007-06), pages 806-812, XP002472608, ISSN: 1286-4579, the whole document in particular: abstract, table 2, page 811, right-hand column, line 10-18, figure 1 * |
| SEMNANI ROSHANAK TOLOUEI ET AL.: "The early response to the infective stage of the filarial parasite Brugia malayi is dominated by inflammatory genes in macrophages". FASEB JOURNAL, vol. 16, no. 5, 22 March 2002 (2002-03-22), page A1038, XP008089531 & ANNUAL MEETING OF PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY; NEW ORLEANS, LOUISIANA, USA; APRIL 20-24, 2002, ISSN: 0892-6638, abstract * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA020412B1 (ru) | Иммунологический мониторинг на основе ip-10 | |
| Nilsson et al. | Comparison of six commercially available SARS-CoV-2 antibody assays—Choice of assay depends on intended use | |
| AU2012244350B2 (en) | Ip-10 based immunological monitoring | |
| CN103119444B (zh) | 区分细菌与病毒感染的标记物和决定因素以及其使用方法 | |
| Villamor et al. | Vitamin D serostatus and dengue fever progression to dengue hemorrhagic fever/dengue shock syndrome | |
| KR102022513B1 (ko) | 감도가 증진된 세포 매개 면역 반응 검정법 | |
| Dziemian et al. | Determination of the relative avidity of the specific IgG antibodies in human toxocariasis | |
| Badiane et al. | Sensitivity and specificity for malaria classification of febrile persons by rapid diagnostic test, microscopy, parasite DNA, histidine-rich protein 2, and IgG: Dakar, Senegal 2015 | |
| WO2008052566A1 (en) | Ccl8 based immunological monitoring | |
| EA005776B1 (ru) | Способ диагностики или прогнозирования основных респираторных бактериальных патогенов у субъекта | |
| Mazhari et al. | Identification of novel Plasmodium vivax proteins associated with protection against clinical malaria | |
| CN118979104A (zh) | 脓毒症相关疾病早期诊断标志物及其用途 | |
| Eisenberg et al. | The serologic response to Cryptosporidium in HIV-infected persons: implications for epidemiologic research | |
| Ramos-Rincon et al. | Cytokine profile levels and their relationship with parasitemia and cardiomyopathy in people with Chagas disease in Spain. A prospective observational study | |
| Tawfiq et al. | Determination the time of toxoplasmosis among pregnant women by using IgG avidity to various Toxoplasma gondii antigens | |
| ES2364173T3 (es) | Control inmunológico basado en ip-10. | |
| Mouhamed et al. | Diagnosis of human toxoplasmosis using rapid chromatographic immunoassay and enzyme-linked immuno-sorbent assay (elisa) compared to molecular technique (pcr) as gold standard technique | |
| Collet et al. | Identification of novel markers for uncomplicated lower genital tract infections and upper genital tract pathology due to Chlamydia trachomatis | |
| Roeder | Longitudinal Quantification of Neutralizing Antibodies and T cell Responses to COVID-19 mRNA Vaccines | |
| Almeria et al. | Recent Developments in the Diagnosis and Detection of the Zoonotic Parasite Toxoplasma gondii Causing Foodborne Disease and Outbreaks | |
| Rainova et al. | Study on the T‐Cell Immune Response in Individuals With HIV and Toxoplasmosis Using ELISPOT | |
| Nabiyeva et al. | LABORATORY DIAGNOSTICS OF BRUCELLOSIS | |
| Abraha et al. | Antibody response in individuals affected with Sars-Cov-2 infection: temporal trends and qualitative and quantitative differences in symptomatic and asymptomatic subjects. A Cross Sectional Analysis. Ab-Covid Study | |
| Akhvlediani et al. | Comparison of total antibody and interferon-γ T-cell responses in patients following infection with brucellosis in Georgia | |
| Vijayakumar et al. | Non-Invasive Materials and Methods in the Diagnosis of Visceral Leishmaniasis and its Treatment Monitoring: A Systematic Review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Registration of transfer of a eurasian patent by assignment |